U.S. drug regulators on Feb. 11 announced they are pushing back a decision on whether to authorize Pfizer’s COVID-19 vaccine for children as young as 6 months old.
Lack of information "made us realize that we needed to see data from a third dose from the ongoing trial in order to make a determination," says FDA chief.
Despite the FDA’s claim that it is committed to transparency, especially for COVID-19 emergency use authorizations (EUAs), the agency first requested 55 years to release the data supporting the approval of Comirnaty after a Freedom of Information Act (FOIA) request was led, and then asked for an extra 20 years to fully comply.
The U.S. Food and Drug Administration’s advisory panel today voted to recommend the agency allow Pfizer to amend its Emergency Use Authorization for its COVID vaccine for children 5 through 11 years old, despite a host of objections from scientists and physicians.
The authors of a study published Sept. 30, in the European Journal of Epidemiology Vaccines said the sole reliance on vaccination as a primary strategy to mitigate COVID-19 and its adverse consequences “needs to be re-examined.”
In an exclusive interview with The Defender, Kristi Dobbs recounted how she’s spent nine months pleading with health agencies to research the neurological injuries she developed after Pfizer’s vaccine, and how she and others are trying to get the word out about the vaccine’s potential risks.
In an exclusive interview with The Defender, Dr. Danice Hertz said people like her who have been seriously injured by COVID vaccines are being dismissed or ignored, and because health officials won’t research their injuries and potential treatments, they have nowhere to turn.
